Latest news with #Placement
Newsweek
11 hours ago
- General
- Newsweek
Map Shows Best Public High Schools Across U.S.
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The map below shows where the best high schools in the country are, according to the U.S. News & World Report's rankings. How Were The Schools Ranked? The rankings include data on more than 24,000 public high schools in all 50 states and the District of Columbia. Almost 18,000 of those schools were ranked on six factors, including their performance on state-required tests and how well they prepare students for college. The graduation rate—the proportion of entering ninth-graders who graduated four academic years later—is also taken into account. Underserved student performance was also a factor, with scores on state assessments aggregated just among students who are Black, Hispanic and from low-income households compared with what is typical in the state for non-underserved students, with parity for higher being the goal. Which Are The Best U.S. High Schools? 1. BASIS Tucson North in Tucson, Arizona BASIS Tucson North scored 100 out of a possible 100. The charter school serves fifth- through 12th-graders, and there are 226 students enrolled in grades nine through 12. Students at the school are required to start taking Advanced Placement classes and exams in ninth grade. 2. Signature School in Evansville, Indiana Signature School scored 99.99. The school offers Advanced Placement and International Baccalaureate courses, and all students are also expected to complete a minimum number of community service hours. There are 378 students in grades nine through 12 and total minority enrollment is 38 percent. Some 9 percent of students are economically disadvantaged. 3. Central Magnet School in Murfreesboro, Tennessee Central Magnet School scored 99.98. The school, ranked first in Tennessee, offers Advanced Placement coursework and exams and the participation rate is 100 percent. The school has 784 students enrolled in grades nine through 12, and 26 percent minority enrollment. 4. Davidson Academy in Reno, Nevada Davidson Academy also scored 99.98. The school, ranked first within Nevada, also offers Advanced Placement coursework and exams with 100 percent of students participating. The school has 121 students in grades nine through 12, with 72 percent minority enrollment. 5. Thomas Jefferson High School for Science and Technology in Alexandria, Virginia Thomas Jefferson High School for Science and Technology scored 99.97. The school uses a STEM-focused curriculum, offering courses such as DNA science, advanced marine biology and automation and robotics. There are 2,015 students in grades nine through 12, and a majority of students (63.3 percent) are Asian. About 13 percent of students are economically disadvantaged. 6. Albuquerque Institute of Math and Science in Albuquerque, New Mexico Albuquerque Institute of Math and Science scored 99.97. The school, ranked first in New Mexico, offers Advanced Placement coursework and exams, and has a 100 percent participation rate. The school has 145 students in grades nine through 12, and the total minority enrollment is 74 percent. About 3 percent of students are economically disadvantaged. A stock photo shows an empty classroom. A stock photo shows an empty classroom. iStock 7. Haas Hall Bentonville in Bentonville, Arkansas Haas Hall Bentonville scored 99.96. The school, ranked first in Arkansas, offers Advanced Placement coursework and exams, and has a 100 percent participation rate. It has 282 students enrolled in grades nine through 12, and the total minority enrollment is 53 percent. About 2 percent of students are economically disadvantaged. 8. Julia R. Masterman Secondary School in Philadelphia, Pennsylvania Julia R. Masterman Secondary School scored 99.96. The school offers Advanced Placement coursework and exams, and the participation rate is 99 percent. The school has 465 students enrolled in grades nine through 12. The total minority enrollment is 60 percent and 100 percent of students are economically disadvantaged. 9. The School for the Talented and Gifted in Dallas, Texas The School for the Talented and Gifted scored 99.95. The school offers 30 Advanced Placement courses and students are required to take 12 to graduate. There are 546 students enrolled in grades nine through 12. The total minority enrollment is 66 percent, and 41 percent of students are economically disadvantaged. 10. Aiken Scholars Academy in Aiken, South Carolina Aiken Scholars Academy scored 99.94. The school offers Advanced Placement coursework and exams, and the participation rate is 100 percent. The school has 179 students in grades nine through 12. The total minority enrollment is 34 percent and 31 percent of students are economically disadvantaged. The full list can be viewed on the U.S. News & World Report's website.
Business Wire
13-08-2025
- Business
- Business Wire
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has entered into securities purchase agreements with several institutional and accredited investors (the "Purchasers") for the purchase and sale of 990 shares of the Company's Series B Convertible Preferred Stock (the 'Preferred Stock') and warrants (the 'Private Placement Warrants') to purchase approximately 6.7 million shares of common stock (the 'Private Placement'). The Company shall use the net proceeds from the Private Placement and Warrant Inducement for working capital and general corporate purposes. The shares of Preferred Stock have a stated value of $1,000 per share and are initially convertible into an aggregate of approximately 4.3 million shares of common stock at a conversion price of $0.23 per share. The Private Placement Warrants will be exercisable following the date on which the Company obtains stockholder approval of the exercise thereof at an initial exercise price of $0.352 per share and expire five years from the original exercise date. The Company also announced today it has entered into a warrant exercise agreement with an existing accredited investor to exercise (i) outstanding warrants to purchase 450,000 shares of the Company's shares of common stock that were issued in August 2024 (the 'August Warrants') and (ii) outstanding warrants to purchase 650,000 shares of the Company's common stock that were issued in October 2024 (the 'October Warrants' and together with the August Warrants, the 'Existing Warrants'), which reduced the exercise prices of the August Warrants from $1.50 to $0.23 per share and the October Warrants from $1.25 to $0.23 per share and provided for the issuance to such investor of new unregistered warrants (the 'New Warrants') to purchase up to an aggregate of 1.43 million shares of the Company's common stock in consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds to the Company of approximately $253,000 (the 'Warrant Inducement'). The New Warrants will have an exercise price of $0.352 per share and will be initially exercisable on the date that stockholder approval of the exercise of the New Warrants is obtained and will expire five years from the date of such approval. The closing of the Private Placement and Warrant Inducement is expected to occur on or about August 14, 2025, subject to the satisfaction of customary closing conditions. The expected aggregate proceeds (before expenses) of the Private Placement and Warrant Inducement will be approximately $1.2 million. The Company shall use the net proceeds from the Private Placement and Warrant Inducement for working capital and general corporate purposes. WallachBeth Capital LLC is acting as the sole placement agent for the Private Placement and financial advisor for the Warrant Inducement. The securities described above will be offered in a private placement exempt from the registration requirements under Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act") and Regulation D promulgated thereunder and in a transaction not involving a public offering and have not been registered under the Act or applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Preferred Stock, the Private Placement Warrants and New Warrants within 15 calendar days after the closing date. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About CyPath® Lung CyPath ® Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath® Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results demonstrated that CyPath® Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit About bioAffinity Technologies, Inc. bioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company's first product, CyPath® Lung, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath® Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies. For more information, visit Forward-Looking Statements Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding the closing of the offering on August 14, 2025. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the ability to close the offering when anticipated and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
&w=3840&q=100)
Business Standard
17-07-2025
- Business
- Business Standard
SBI stock hits highest level in CY-2025 on QIP plan; more upside ahead?
State Bank of India (SBI) share price today Shares of State Bank of India (SBI) were up 1 per cent at ₹840.35 on the BSE in Thursday's intra-day trade after the state-owned lender launched a share sale to institutional investors to raise upto ₹25,000 crore. The stock price of public sector bank was trading higher for the fourth straight day, gaining 4 per cent during the period. SBI shares traded at their highest level in calendar year 2025 (CY25), surpassing the previous current year high of ₹835.40 touched on April 22, 2025. However, thus far in the CY25, SBI has underperformed the market, by gaining 5 per cent, as compared to 5.3 per cent rise in the BSE Sensex. At 09:46 AM; SBI was quoting 0.14 per cent higher at ₹832.70, as against 0.10 per cent decline in the benchmark index. SBI, the largest lender in the country, has launched a share sale to institutional investors to raise upto ₹25,000 crore, the biggest qualified institutional placement (QIP) so far by an Indian firm, and has set a floor price of ₹811.05, which is at a 2.5 per cent discount on Wednesday's closing price. Separately, the bank's board approved another ₹20,000 crore fund raise by issuing bonds. Life Insurance Corporation, Singapore's GIC, Capital International, and ICICI Prudential AMC are some of the investors in the share sale, Business Standard reported quoting investment-banking sources. SBI in Preliminary Placement Document said the Bank intends to utilize the net Proceeds towards augmentation of Bank's TierI capital base to meet Bank's future capital requirements and to support growth plans and to enhance the business of the Bank. Indian Economy The Reserve Bank of India (RBI) has projected the real GDP to grow at 6.5 per cent in 2025-2026, same as in 2024-2025, supported by buoyant rural demand, revival in urban demand, an uptick in investment activity on the back of above-average capacity utilisation, government's continued thrust on capex and congenial financial conditions. The continued momentum in various high frequency indicators of services sector, robust agricultural production and above normal southwest monsoon forecasts, and strong goods and services tax (GST) collections underscore the sustained momentum and resilience of the economy. The soundness and resilience of Scheduled Commercial Banks (SCBs) are bolstered by robust capital buffers, multi-decadal low non-performing loans and strong earnings. The Indian financial sector remained strong and resilient amidst global headwinds. SCBs continued to record improvement in their asset quality, with the gross non-performing asset (GNPA) ratio and net non performing asset (NNPA) ratio declining to multi-decadal lows of 2.3 per cent and 0.5 per cent, respectively, SBI said in Preliminary Placement Document. ALSO READ | Godrej Properties shares up 2% on acquiring land parcel in Raipur; details Axis Securities view on SBI SBI remains well-poised to sustain its growth momentum, supported by its comfortable loan-to-deposit ratio (LDR), which provides it with levers to accelerate credit growth. With a bulk of its loan book either being MCLR-linked or Fixed rate, the impact of yield repricing would be with a lag, instilling confidence in the management to protect NIMs at ~3 per cent. Analysts at Axis Securities believe SBI could continue to deliver a sustainable RoA of 1 per cent over the medium term, supported by healthy growth visibility across segments, strengthening deposit franchise with focus on CASA deposits, ramping up the fee income profile, and controlled Opex and steady provisions. Meanwhile, those at Motilal Oswal Financial Services believe the bank is well-positioned for sustainable credit growth supported by robust underwriting and a potential corporate capex recovery. "SBI has delivered a robust set of performances in recent years, propelled by steady business and revenue growth as well as controlled provisions. NIM has contracted in recent quarters, and the management has guided for broadly stable margins (negative bias depending on the quantum and timing of rate cuts). The bank has levers in place (CD ratio, MCLR re-pricing, asset mix improvement, etc.) to mitigate the impact arising from moderation in lending yields," they said in a recent report. SBI stock is Motilal Oswal's preferred pick within the PSU Bank space. It has a 'Buy' rating on the stock with a share price target of ₹925. Analysts at IIFL Capital, too, prefer SBI among PSBs, betting on its steady market share, superior asset quality, increased digital push, and better loan mix. The brokerage has a 'Buy' rating with a target price of ₹930 per share.
Yahoo
27-06-2025
- Business
- Yahoo
Issue of Shares and Cleansing Notice
Settlement of Tranche 1 of the Placement for A$18.2m TORONTO and PERTH, Australia, June 26, 2025 (GLOBE NEWSWIRE) -- Further to the ASX announcement on 20 June 2025, Cygnus Metals Limited ('Cygnus' or the 'Company') advises that it has issued a total of 211,627,907 fully paid ordinary shares ('Shares') at A$0.086 each under Tranche 1 of the Placement, raising a total of A$18,200,000 (before costs). The Shares were issued under the Company's existing capacity under ASX Listing Rules 7.1 (126,702,591) and 7.1A (84,925,316). A further 1,162,790 Shares are intended to be issued under Tranche 2 of the Placement to Non-Executive Director Raymond Shorrocks, or his nominees, subject to receipt of shareholder approval at a general meeting to be held in August 2025. In addition, the Company has issued a total of 306,129 Shares to employees on conversion of 350,000 vested Performance Rights issued under the Company's previous Employee Securities Incentive Plan. Cygnus issued the Shares without disclosure under section 708A(5) of the Corporations Act 2001 (Cth) ('Act'). With reference to those Shares issued, in accordance with section 708A(6) of the Act, the Company gives notice under paragraph 708A(5)(e) that: 1. the Company issued the Shares without disclosure under Part 6D.2 of the Act; and 2. as at the date of this notice: a) the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company; b) the Company has complied with sections 674 and 674A of the Act; and c) other than as set out below, there is no excluded information within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Act. As previously announced, the Company has ongoing exploration and drill programs at its Chibougamau Copper-Gold Project in Quebec and is awaiting assay results from its current drill program (which remains ongoing). The Company will announce its assay results when it is in a position to complete the collation and interpretation of all data and in accordance with its continuous disclosure obligations, the JORC Code and the ASX Listing Rules. This announcement has been authorised for release by the Board of Directors of Cygnus. David SouthamExecutive ChairT: +61 8 6118 1627E: info@ Ernest MastPresident & Managing DirectorT: +1 647 921 0501E: info@ Media:Paul Armstrong Read Corporate+61 8 9388 1474 About Cygnus Metals Cygnus Metals Limited (ASX: CY5, TSXV: CYG) is a diversified critical minerals exploration and development company with projects in Quebec, Canada and Western Australia. The Company is dedicated to advancing its Chibougamau Copper-Gold Project in Quebec with an aggressive exploration program to drive resource growth and develop a hub-and-spoke operation model with its centralised processing facility. In addition, Cygnus has quality lithium assets with significant exploration upside in the world-class James Bay district in Quebec, and REE and base metal projects in Western Australia. The Cygnus team has a proven track record of turning exploration success into production enterprises and creating shareholder value.
Miami Herald
20-06-2025
- Business
- Miami Herald
Alpha Growth PLC - Providence Life Granted Isle of Man Branch License
Providence Life Receives Isle of Man Branch License LONDON, UK / ACCESS Newswire / June 20, 2025 / Alpha Growth plc, ( a leading global financial services specialist in the multi-billion dollar market of longevity assets and insurance linked asset and wealth management is pleased to announce that one of its group companies, Providence Life Assurance Company (Bermuda) Limited ("Providence Life Assurance"), a leading provider of bespoke life insurance solutions for ultra-high net worth ("UHNW") individuals and family offices, has been granted a branch license in the Isle of Man. The new branch, operating under the name Alpha PPLI will cater to the sophisticated wealth planning needs of clients across the UK, Europe, Middle East and Asia. The Isle of Man Financial Services Authority issued the permit to Providence Life Assurance on May 23, 2025, under section 22 of the Insurance Act 2008, authorizing the company to conduct both Class 1 and Class 2 insurance business with immediate effect. Alpha PPLI builds upon Providence Life Assurance's established expertise in Private Placement Life Insurance ("PPLI") and Private Placement Variable Annuities ("PPVA"), offering tailored solutions designed to address the complex financial and succession planning requirements of UHNW individuals and family offices. The branch aims to provide a full suite of customized insurance structures, supported by a team with decades of collective industry experience and backed by the financial strength of parent company Alpha Growth plc. Alpha PPLI is lead by its Chief Executive Julian Melling and Business Development Executive Richard Turnbull, both based in the Isle of Man with significant recognized experience in the high net worth life insurance industry. "Our expansion into the Isle of Man through Alpha PPLI marks a significant milestone in Providence Life Assurance's growth strategy. This new branch enhances our ability to deliver world-class, flexible insurance solutions to discerning clients in key international markets," said Gobind Sahney, Chairman & CEO of Alpha Growth plc and Providence Life Assurance. "After many years in this industry, I am pleased to lead the strategic expansion of Providence Life Assurance's international business. This marks a pivotal moment for UHNW life insurance, opening up an exciting future for Providence Life Assurance and the Alpha Growth group of companies, as we enhance our ability to serve the sophisticated needs of UHNW clients and family offices across key international markets." said Julian Melling, jm@ Chief Executive of Alpha PPLI. Providence Life Assurance is renowned for its independent, client-focused approach, delivering best-in-class service and innovative insurance products. The launch of Alpha PPLI in the Isle of Man underscores the company's commitment to supporting the wealth management objectives of UHNW clients and family offices in the UK, Europe, and Asia. About Providence Life Assurance Company (Bermuda) Limited: Providence Life Assurance specializes in providing customized life insurance products, including PPLI and PPVA, to ultra-high net worth individuals and institutions. The company operates under the regulatory oversight of the Bermuda Monetary Authority and is part of Alpha Growth plc, a global leader in insurance-linked wealth management. About Alpha Growth plc Specialist in Life Insurance, Esoteric and Longevity Assets Alpha Growth plc is a financial advisory business providing specialist consultancy, advisory, and supplementary services to institutional and qualified investors globally in the multi-billion dollar market of longevity assets and insurance linked asset and wealth management. Building on its well-established network, the Alpha Growth group has a unique position in the insurance and asset services and investment business with global reach. ***END*** This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@ or visit SOURCE: Alpha Growth PLC
